Nissen N I, Pajak T F, Leone L A, Bloomfield C D, Kennedy B J, Ellison R R, Silver R T, Weiss R B, Cuttner J, Falkson G, Kung F, Bergevin P R, Holland J F
Cancer. 1980 Jan 15;45(2):232-5. doi: 10.1002/1097-0142(19800115)45:2<232::aid-cncr2820450206>3.0.co;2-f.
The epipodophyllotoxin derivative VP 16--213 (NSC 141540) was studied by the Cancer and Leukemia Group B in a broad phase II trial at three dose levels: 60 mg/m2, 90 mg/m2, and 135 mg/m2 I.V. twice weekly. No correlation between dose of VP 16--213 and response frequency in a particular disease category could be demonstrated. Of the 382 patients, 8% obtained a complete (CR) or partial remission (PR), 8% showed improvement, and 14% had stable disease. By tumor type the best responses were obtained in lymphomas (8/31 CR + PR), uterus (2/9), prostate (1/5), rhabdomyosarcoma (2/6), neuroblastoma (2/4), colon/rectum (5/81), other gastrointestinal (4/32). In lung tumors, 4/80 patients obtained CR or PR. VP 16--213 has definite antineoplastic activity but the response frequency with the twice weekly schedule may be lower than that reported with other schedules.
